The Food and Drug Administration (FDA) has approved Susvimo ® (ranibizumab injection) for the treatment of patients with ...

Genentech's ranibizumab injection (Susvimo) has received FDA approval for the treatment of diabetic retinopathy. The ...

The FDA approved Susvimo 100 mg/mL to treat diabetic retinopathy, according to a press release from Genentech.The approval was supported by positive 1-year data from the phase 3 Pavilion study in ...

Susvimo is the first and only FDA-approved, continuous delivery treatment shown to maintain vision in people with DR with ...

Roche RHHBY announced today that the FDA has approved a label expansion of ophthalmology drug Susvimo (ranibizumab injection). The regulatory body approved the drug Susvimo for the treatment of ...

One-year results from the Pavilion study showed patients who received Susvimo (ranibizumab) refilled every nine months ...

Researchers said a single daytime sample of serum 17-hydroxyprogesterone and/or androstenedione is sufficient to monitor ...

Susvimo is also approved to treat diabetic macular edema and age-related macular degeneration, and the medication, ...

Susvimo can help people with diabetic retinopathy (DR) maintain their vision and prevent progression to blindness with only ...

Credit: Genentech. Susvimo is indicated for intravitreal use via the Susvimo ocular implant. For patients with diabetic retinopathy, refills of Susvimo are administered every 36 weeks ...

Susvimo can help people with diabetic retinopathy (DR) maintain their vision and prevent progression to blindness with only one treatment every nine months – – Susvimo’s innovative ...